Key facts
- Talam Biotech’s last known valuation is $10.5M (Jan 2025).
- It has raised $22.3M; the latest was Later Stage VC ($5.0M) in Jan 2025.
- Notable investors include Enterprise Ireland, Connecticut Innovations, AME Cloud Ventures, SVG Ventures|THRIVE, Cultivation Capital — 16 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 16 names
- ·Watchlist + deal alerts for Talam Biotech
- ·The full record, as it builds
Funding rounds
No funding rounds for Talam Biotech are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Talam Biotech
Developer of environmental bio-remediation products designed to reduce toxins in crops and clean contaminated soil and water. The company's microbial keys, derived from natural sources, reduce heavy metal uptake by inhibiting the bioavailability of heavy metals to plants, enabling microbes to reduce contaminants and remediate soil pollutants.
- Sector
- Materials and Resources
- HQ
- Groton, CT, United States
- Founded
- 2012
- Employees
- 16
- Website
- talam.com/
- Ownership
- Privately Held (backing)
Talam Biotech doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Talam Biotech shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Talam Biotech in its N-PORT filings yet. We sweep new filings monthly.